Viyash Scientific Ltd

Viyash Scientific Employee Stock Options

Viyash Scientific allotted 1,107,309 ESOP shares at exercise prices of ₹86 and ₹101. Paid-up capital rose to ₹88.33 Crore post-allotment.

Viyash Scientific Merger & Restructuring

Viyash Scientific Limited announced receipt of Italian regulatory approval for its subsidiary Alivira Animal Health's acquisition of BioForLife Italia S.r.l. The transaction completion timeline is extended.

Viyash Scientific Acquisition

Viyash Scientific Limited received Italian regulatory approval for its proposed 100% acquisition of BioForLife Italia S.r.l., with the completion timeline now extended by two months.

Viyash Scientific Employee Stock Options

Viyash Scientific Limited allotted 6,12,773 equity shares following the exercise of options under its ESOP 2020 and 2026 schemes. The company's paid-up capital increased to Rs. 88.10 Crore.

Viyash Scientific Investor Presentation: Key Takeaways

Viyash Scientific delivered strong Q1 FY27 results with 19.5% revenue growth and significant margin expansion. Integration is complete, and the company is now virtually debt-free, pivoting toward oncology and companion animal health.

Call

Guides 18% growth

Viyash Scientific Earnings Call Transcript: Key Takeaways

Viyash reports a robust Q1FY27 with 20% revenue growth and significantly expanded EBITDA margins at 21.6%. The company is essentially net-debt free following successful integration and is pivoting toward high-potent oncology products.

Call

Guides 18% growth

Viyash Scientific Investor Presentation: Key Takeaways

Viyash Scientific reported strong Q1 FY27 results with 19.5% YoY revenue growth and 59.2% EBITDA growth, driven by integration success and operational leverage.

Viyash Scientific Q1 FY27 Results: Net Profit ₹79.3 Cr, Up 114.9% YoY

Viyash Scientific Ltd reported revenue from operations of ₹946.4 Cr (+19.6% YoY) and net profit of ₹79.3 Cr (+114.9% YoY) for Q1 FY27.

Key figure

Net profit ₹79.3 Cr · +114.9% YoY

Viyash Scientific Earnings Call: Key Takeaways

Viyash Scientific targets a $1Bn revenue platform by 2032 through the merger of Sequent and Viyash Life Sciences, focusing on animal and human health.

Viyash Scientific Earnings Call: Key Takeaways

Viyash reports a transformative Q4 FY26 with EBITDA surpassing ₹200cr. Revenue rose 19.1% YoY to ₹920cr, driven by integration synergies and a shift toward high-potent human and animal health products.

Viyash Scientific Earnings Call: Key Takeaways

Viyash delivered a breakout FY26 with Q4 EBITDA crossing 200cr, marking a successful business integration.

Viyash Scientific Earnings Call: Key Takeaways

Viyash Q4 FY26 revenue reached ₹9,200 Mn with 21.7% EBITDA margins. Management highlights successful integration and a deleveraged balance sheet.

Viyash Scientific Q4 FY26 Results: Turns Profitable, Net Profit ₹66.4 Cr

Viyash Scientific Ltd reported revenue from operations of ₹920 Cr (+19.1% YoY) and net profit of ₹66.4 Cr for Q4 FY26.

Key figure

Net profit ₹66.4 Cr